Relative bioavailability compares systemic drug exposure from a test formulation with exposure from a reference formulation. It accounts for differences in administered amounts and is commonly used in formulation comparison studies.
Relative Bioavailability
Relative bioavailability compares systemic drug exposure from a test formulation with exposure from a reference formulation. It accounts for differences in administered amounts and is commonly used in formulation comparison studies.
\(F_{\mathrm{rel}} = (AUC_{\mathrm{test}}/AUC_{\mathrm{reference}}) \times (Dose_{\mathrm{reference}}/Dose_{\mathrm{test}})\)
What this formula means
Scientific principle
Principle
Two formulations containing the same active compound can produce different systemic exposures because of differences in dissolution, absorption and formulation characteristics. Relative bioavailability quantifies their exposure ratio.
Derivation
Let AUC_test represent systemic exposure from the test formulation.
Let AUC_reference represent exposure from the reference formulation.
For linear pharmacokinetics, exposure is proportional to bioavailable amount.
Correct the exposure ratio for any difference in administered amounts.
Therefore, F_rel = (AUC_test/AUC_reference) × (Dose_reference/Dose_test).
When the administered amounts are equal, the expression simplifies to the ratio of the two AUC values.
Final Result
F_rel = (AUC_test/AUC_reference) × (Dose_reference/Dose_test).
Variables and their meanings
Frel
Relative bioavailability.
AUCtest
Area under the concentration-time curve for the test formulation.
AUCreference
Area under the concentration-time curve for the reference formulation.
Dosetest
Administered amount of the test formulation.
Dosereference
Administered amount of the reference formulation.
SI units and conversions
Frel
Dimensionless ratio or percentage.
AUC
mg·h·L⁻¹.
Dose
mg or μg.
Conditions of use
The test and reference formulations should contain the same active drug for a direct comparison.
Dose differences must be normalized.
The study should use comparable sampling and analytical procedures.
Linear pharmacokinetics are assumed for straightforward dose normalization.
Study design should control relevant sources of variability.
Limitations and assumptions
Relative bioavailability does not establish absolute bioavailability.
AUC comparison alone does not fully characterize absorption rate.
Different study conditions can influence measured exposure.
Nonlinear pharmacokinetics can invalidate simple dose normalization.
Relative bioavailability is not automatically equivalent to regulatory bioequivalence.
Step-by-step worked examples
| Problem | Solution | Answer |
|---|---|---|
A test formulation produces an AUC of 60 mg·h·L⁻¹, while the reference formulation produces 50 mg·h·L⁻¹. The administered amounts are equal. Calculate relative bioavailability. |
| Relative bioavailability is 120%. |
A test formulation has an AUC of 36 mg·h·L⁻¹ and a modeled administered amount of 150 mg. A reference formulation has an AUC of 40 mg·h·L⁻¹ and an administered amount of 100 mg. Calculate relative bioavailability. |
| Relative bioavailability is approximately 60%. |
Real-world applications
Comparing pharmaceutical formulations.
Studying generic and reference products.
Evaluating formulation changes.
Analyzing drug absorption differences.
Supporting pharmaceutical development research.
Formula Meaning
Relative bioavailability compares systemic drug exposure from a test formulation with exposure from a reference formulation. It accounts for differences in administered amounts and is commonly used in formulation comparison studies.
Sources and further reading
No source has been supplied for this item yet. Treat the claim as needing editorial verification.